Tafluprost: A novel prostaglandin analog for treatment of glaucoma

Advances in Therapy

Volumn 28, Issue 9, 2011, Pages 707-715

  Mina, B Pantcheva ^a   Leonard, K Seibold ^a   Nida, S Awadallah ^b   Malik, Y Kahook ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Rose Family Medicine   (United States)

Author keywords

Intraocular pressure; Ocular surface; Prostaglandin analog; Tafluprost

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST; PLACEBO; TAFLUPROST;

CONJUNCTIVAL HYPEREMIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXFOLIATION SYNDROME; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OPEN ANGLE GLAUCOMA; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VITAL SIGN;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F;

EID: 82455164175     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0055-8     Document Type: Review

References (40)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130: 429-440
2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120: 1268-1279 (Pubitemid 36105431)
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 701-713 (Pubitemid 34620348)
4. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: The Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004;15: 102-106 (Pubitemid 38457128)
5. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F2a derivatives with prostanoid FP-receptor agonistic activity as potent ocular hypotensive agents. Biol Pharm Bull. 2003;26: 1691-1695 (Pubitemid 39663527)
6. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid receptor FP agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78: 767-776 (Pubitemid 38252953)
7. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242: S14-S19
8. Sutton A, Gilvarry A, Ropo A. A comparative placebo-controlled study of prostanoid fluoroprostaglandin receptor agonist tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther. 2007;23: 359-365 (Pubitemid 350195060)
9. Sutton A, Gouws P, Ropo A. Tafluprost a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46: 400-406
10. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf). 2008;242: S7-S13
11. Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4: 163-170
12. FukanoY, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009;37: 1622-1634
13. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19: 501-515 (Pubitemid 38030237)
14. Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys. J Glaucoma. 2011. Epub ahead of print
15. Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: Effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24 hour variation. Invest Ophthalmol Vis Sci. 2005;46: 2006-2011
16. Ota T, Aihara M, Saeki T, et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91: 673-676 (Pubitemid 46716541)
17. Akaishi T, Odani-Kawabada N, Ishida N, et al. Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther. 2009;25: 401-408
18. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol. 2005;16: 79-83 (Pubitemid 43790798)
19. Michelson G, Langhans MJ, Groh, MJ. Perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open angle glaucoma. J Glaucoma. 1996;5: 91-98 (Pubitemid 26139159)
20. Yamazaki Y, Hayamizu F. Comparison of flow velocity of ophthalmic artery between primary open angle glaucoma and normal tension glaucoma. Br J Ophthalmol. 1995;79;732-734
21. Findl O, Rainer G, Dallinger S, et al. Assessment of optic disk blood flow in patients with open-angle glaucoma. Am J Ophthalmol. 2000;130: 589-596
22. Grunwald JE, Piltz J, Hariprasad SM, et al. Optic nerve and choroidal circulation in glaucoma. Invest Ophthalmol Vis Sci. 1998: 39;2329-2336 (Pubitemid 28485644)
23. Izumi N, Nagaoka T, Sato E, et al. Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther. 2008;24: 21-526
24. Akaishi T, Kutrashima H, Odani-Kaeabata N, et al. Effects of repeated administration of tafluprost, latanoprost, and travoprost on optic nerve blood flow in conscious normal rabbits. J Ocul Pharmacol Ther. 2010;26: 181-186
25. Dong Y, Watabe H, Su G, et al. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res. 2008;87: 251-256
26. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin PGF2a analogues on endothelin-1-induced impairment of rabbit ocular blood flow: Comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91: 853-859
27. Mayama C, Ishii K, Saeki T, et al. Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest Ophthamol Vis Sci. 2010;51: 4117-4124
28. Kanamori A, Naka M, Fukuda M, et al. Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol. 2009;247: 1353-1360
29. Bull ND, Johnson TV, Welsapar G, et al. Use of an adult retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci. 2011;52: 3309-3320
30. Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci. 1984;25: 1453-1457 (Pubitemid 15191102)
31. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chilosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 2008;348: 175-178 (Pubitemid 350266247)
32. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 2009;41: 118-122
33. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33: 303-312 (Pubitemid 351507760)
34. Liang H, Baudouin C, Pauly A, et al. Conjunctival and corneal reactions in rabbits following shortand repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92: 1275-1282
35. Traverso CE, Ropo A, Papadia M, et al. A Phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26: 97-104
36. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked Phase III study. Acta Ophthalmol. 2010;88: 12-19
37. Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;8: 1459-1463
38. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88: 329-336
39. Hommer A, Mohammed RO, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26: 1905-1913
40. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Avd Ther. 2011;28: 575-585.